Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mobile phones

- PMLiVE

Third time lucky as MannKind’s inhaled insulin is approved

US FDA backs new diabetes treatment Afrezza

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

- PMLiVE

ADA: Sanofi shifts focus to embrace integration in diabetes

Pascale Witz unveils company's ambitions at ADA conference

- PMLiVE

ADA: Empagliflozin overcomes FDA concerns

Boehringer and Lilly expect decision on diabetes treatment by end of 2014

- PMLiVE

Sanofi and Medtronic to develop drug-device combos in diabetes

Companies tell PMLiVE their new alliance will take an ‘open innovation’ approach

- PMLiVE

ADA: AZ plans to file Onglyza/Forxiga pill by year-end

Diabetes prospects could help justify decision to turn down Pfizer bid

- PMLiVE

ADA: Lilly/Boehringer insulin glargine matches Lantus

Biosimilar demonstrates equal efficacy to Sanofi’s big-selling diabetes treatment

- PMLiVE

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

- PMLiVE

J&J brings its Care4today mobile adherence programme to the UK

Launches the mobile app in its first market outside the US

- PMLiVE

Novo Nordisk: Tresiba makes a solid start

Long-acting insulin capturing share of diabetes market

- PMLiVE

GSK gets OK in US for diabetes drug albiglutide

Once-weekly Tanzeum will compete against Victoza and Byetta after FDA approval

- PMLiVE

Lilly to use real-world data in diabetes collaboration

Partners with T1D Exchange to research ways to provide type 1 diabetes care

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links